metformin has been researched along with Status Epilepticus in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Status Epilepticus: A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has exhibited anti-inflammatory and neuroprotective properties in numerous studies." | 5.62 | Metformin ameliorates the status epilepticus- induced hippocampal pathology through possible mTOR modulation. ( Anand, S; Bhatia, A; Bojja, SL; Joshi, R; Medhi, B; Minz, RW, 2021) |
| "Metformin has exhibited anti-inflammatory and neuroprotective properties in numerous studies." | 1.62 | Metformin ameliorates the status epilepticus- induced hippocampal pathology through possible mTOR modulation. ( Anand, S; Bhatia, A; Bojja, SL; Joshi, R; Medhi, B; Minz, RW, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bojja, SL | 1 |
| Medhi, B | 1 |
| Anand, S | 1 |
| Bhatia, A | 1 |
| Joshi, R | 1 |
| Minz, RW | 1 |
| Chen, J | 1 |
| Zheng, G | 1 |
| Guo, H | 1 |
| Shi, ZN | 1 |
| Jiang, J | 1 |
| Wang, XY | 1 |
| Yang, X | 1 |
| Liu, XY | 1 |
2 other studies available for metformin and Status Epilepticus
| Article | Year |
|---|---|
Metformin ameliorates the status epilepticus- induced hippocampal pathology through possible mTOR modulation.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Dose-Response Relationship, Dr | 2021 |
The effect of metformin treatment on endoplasmic reticulum (ER) stress induced by status epilepticus (SE) via the PERK-eIF2α-CHOP pathway.
Topics: Animals; Apoptosis; Convulsants; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation F | 2018 |